Algert Global LLC Purchases 21,223 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Algert Global LLC increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 119.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,048 shares of the company’s stock after acquiring an additional 21,223 shares during the period. Algert Global LLC’s holdings in TransMedics Group were worth $6,131,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC bought a new position in shares of TransMedics Group in the second quarter worth $47,000. USA Financial Formulas bought a new position in TransMedics Group in the 3rd quarter worth about $55,000. J.Safra Asset Management Corp raised its holdings in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares in the last quarter. Signaturefd LLC boosted its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating and issued a $109.00 target price on shares of TransMedics Group in a research note on Friday. Stephens raised their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Robert W. Baird cut their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Canaccord Genuity Group lowered their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Trading Down 4.2 %

Shares of TMDX stock opened at $76.04 on Friday. The stock has a market capitalization of $2.55 billion, a PE ratio of 80.89 and a beta of 2.08. TransMedics Group, Inc. has a 1-year low of $67.77 and a 1-year high of $177.37. The business has a 50-day moving average of $119.18 and a 200 day moving average of $137.70. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.12) earnings per share. As a group, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at $3,714,902.10. The trade was a 32.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock worth $5,230,528 in the last ninety days. 7.00% of the stock is owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.